January 8, 2020

OWP Pharmaceuticals Announces Pre-IND Acknowledgement and Patent Application for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder

Share this press release:

Document loads below this notification.

Additional Press Releases

May 20, 2024 / Press Release

OWP Pharmaceuticals Announces FDA Filing Acceptance for New Drug Application of SUBVENITE® (lamotrigine) Oral Suspension

August 1, 2023 / Press Release

OWP Pharmaceuticals Announces IND Authorization for First Oral Liquid Formulation of Trazodone for Treatment of MDD

March 14, 2023 / Press Release

Powering Social Enterprise with Profit and Purpose: The Tandem Hybrid by Scott Boyer, Jeremy Gudauskas, and Mike Hamel